









Markets
/
Stocks
/
nasdaq-stro
/

Sutro Biopharma Inc

STRO

1.020USD

-0.080-7.27%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

86.41MMarket Cap

LossP/E TTM



Sutro Biopharma Inc

1.020

-0.080-7.27%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Sutro Biopharma Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sutro Biopharma Inc's Score

Industry at a Glance

Industry Ranking

93 / 407

Overall Ranking

207 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

2.686

Target Price

+139.80%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Sutro Biopharma Inc Highlights

StrengthsRisks

Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.

Growing

The company is in a growing phase, with the latest annual income totaling USD 62.04M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 62.04M.

Overvalued

The company’s latest PE is -0.44, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 53.02M shares, decreasing 36.96% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 103.32K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.66.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 8.65, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 63.74M, representing a year-over-year increase of 147.98%, while its net profit experienced a year-over-year increase of 76.05%.

Score

Industry at a Glance

Previous score

8.65

Change



Financials

5.45

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Sutro Biopharma Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 7.07, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.44, which is -59.03% below the recent high of -0.18 and -722.29% above the recent low of -3.60.

Score

Industry at a Glance

Previous score

7.07

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 93/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Sutro Biopharma Inc is 2.00, with a high of 5.00 and a low of 0.80.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

2.686

Target Price

+144.16%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Sutro Biopharma Inc

STRO

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 6.85, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.35 and the support level at 0.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.99

Change

-0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.001

Neutral

RSI(14)

50.770

Neutral

STOCH(KDJ)(9,3,3)

22.209

Sell

ATR(14)

0.143

Low Volatility

CCI(14)

-48.537

Neutral

Williams %R

57.290

Sell

TRIX(12,20)

1.089

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.090

Sell

MA10

1.098

Sell

MA20

1.007

Buy

MA50

0.948

Buy

MA100

0.878

Buy

MA200

1.016

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 62.54%, representing a quarter-over-quarter decrease of 19.38%. The largest institutional shareholder is The Vanguard, holding a total of 4.12M shares, representing 4.85% of shares outstanding, with 4.89% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Affinity Asset Advisors LLC

752.72K

Suvretta Capital Management, LLC

6.49M

-13.05%

Kynam Capital Management LP

5.09M

-6.49%

Millennium Management LLC

4.73M

+573.00%

The Vanguard Group, Inc.

Star Investors

4.12M

-6.37%

Velan Capital Investment Management LP

3.06M

+197.09%

Acadian Asset Management LLC

3.04M

-2.95%

Merck & Co Inc

2.72M

Vestal Point Capital, LP

2.60M

Tang Capital Management, LLC

2.56M

+1180.79%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 2.50, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.76. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.